Valneva (NASDAQ:VALN) Stock Price Down 3.6% - Should You Sell?

Valneva SE (NASDAQ:VALN - Get Free Report) was down 3.6% during mid-day trading on Tuesday . The stock traded as low as $6.25 and last traded at $6.34. Approximately 13,562 shares changed hands during trading, a decline of 81% from the average daily volume of 71,096 shares. The stock had previously closed at $6.57.

Wall Street Analysts Forecast Growth

VALN has been the topic of several recent research reports. Guggenheim reduced their price target on Valneva from $17.00 to $15.00 and set a "buy" rating on the stock in a research report on Monday, March 24th. HC Wainwright reissued a "buy" rating and set a $17.00 target price on shares of Valneva in a research note on Tuesday, April 15th.

Valneva Stock Up 3.0 %

The stock has a market capitalization of $549.49 million, a PE ratio of -50.54 and a beta of 1.85. The stock's 50-day moving average price is $6.81 and its two-hundred day moving average price is $5.72. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78.

Valneva (NASDAQ:VALN - Get Free Report) last released its earnings results on Thursday, March 20th. The company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.32). The company had revenue of $56.48 million during the quarter, compared to analysts' expectations of $55.64 million. Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. As a group, analysts expect that Valneva SE will post 0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On Valneva

Several large investors have recently bought and sold shares of VALN. GAMMA Investing LLC bought a new position in Valneva in the first quarter valued at about $94,000. Wells Fargo & Company MN boosted its holdings in Valneva by 14.3% in the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock worth $1,079,000 after buying an additional 30,859 shares during the period. Finally, ABC Arbitrage SA bought a new stake in Valneva during the 4th quarter valued at approximately $84,000. 11.39% of the stock is currently owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.